Encompass Health Corporation – Consensus ‘none’ rating and 12.4% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Encompass Health Corporation with ticker code (EHC) now have 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘none’. The range between the high target price and low target price is between $120.00 and $110.00 calculating the mean target price we have $115.67. Given that the stocks previous close was at $102.87 this is indicating there is a potential upside of 12.4%. The day 50 moving average is $98.73 while the 200 day moving average is $88.44. The market capitalization for the company is 10.33B. Currently the stock stands at: $102.50 USD

The potential market cap would be $11,611,502,464 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 24.12, revenue per share of $52.26 and a 8.38% return on assets.

Encompass Health Corporation is a provider of post-acute healthcare service. The Company manages its operations through its inpatient rehabilitation segment. The Company is the owner and operator of rehabilitation hospitals. It operates hospitals in approximately 37 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. The Company operates approximately 156 inpatient rehabilitation hospitals. It provides specialized rehabilitative treatment on an inpatient basis. The Company’s inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It also provides rehabilitative care for patients recovering from injury or illness, using advanced technology and treatments to maximize recovery. Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages technologies and advanced therapies and leads to superior outcomes.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search